Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market 2022-2028

December 2022 | 87 pages | ID: GF011C9A2F7BEN
Gen Consulting Company

Abstracts

According to market research study published by Gen Consulting Company, the market size of the global pharmaceutical CDMO sector is expected to rise by USD 78.0 billion with a CAGR of 6.2% by the end of 2028.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical CDMO market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the pharmaceutical CDMO industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the CMO type, CRO research phase, and region. The global market for pharmaceutical CDMO can be segmented by CMO type: active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. The active pharmaceutical ingredient (API) manufacturing segment is estimated to account for the largest share of the global pharmaceutical CDMO market. Pharmaceutical CDMO market is further segmented by CRO research phase: pre-clinical, phase I, phase II, phase III, phase IV. The phase III segment held the largest revenue share in 2021. Based on region, the pharmaceutical CDMO market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the pharmaceutical CDMO market.

The finished dosage formulation (FDF) development and manufacturing market is further segmented into solid dose formulation, liquid dose formulation, injectable dose formulation. The solid dose formulation segment held the largest share of the global pharmaceutical CDMO market in 2021 and is anticipated to hold its share during the forecast period. Furthermore, the API manufacturing market has been categorized into small molecule, large molecule, high potency API (HPAPI). In 2021, the small molecule segment made up the largest share of revenue generated by the pharmaceutical CDMO market.

Market Segmentation

By CMO type: active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging

By CRO research phase: pre-clinical, phase I, phase II, phase III, phase IV

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global pharmaceutical CDMO market with some of the key players being Baxter Pharmaceutical Solutions LLC, Boehringer Ingelheim GmbH, Catalent Inc., CMIC Holdings Co., Ltd., Covance Inc., Hangzhou Tigermed Consulting Co., Ltd., ICON plc, IQVIA Holdings Inc., Jubilant Life Sciences Ltd., Lonza Group AG, Novotech Pty Ltd., PAREXEL International Corporation, Patheon Inc., Pfizer CentreSource, PPD, Inc., Recipharm AB, Samsungbioepis Co,. Ltd., Syneos Health Inc., WuXi AppTec Inc., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global pharmaceutical CDMO market.
• To classify and forecast the global pharmaceutical CDMO market based on CMO type, CRO research phase, region.
• To identify drivers and challenges for the global pharmaceutical CDMO market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pharmaceutical CDMO market.
• To identify and analyze the profile of leading players operating in the global pharmaceutical CDMO market.

Why Choose This Report

• Gain a reliable outlook of the global pharmaceutical CDMO market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY CMO TYPE

Active pharmaceutical ingredient (API) manufacturing
Finished dosage formulation (FDF) development and manufacturing
Secondary packaging

PART 6. MARKET BREAKDOWN BY CRO RESEARCH PHASE

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

PART 7. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 8. KEY COMPANIES

Baxter Pharmaceutical Solutions LLC
Boehringer Ingelheim GmbH
Catalent Inc.
CMIC Holdings Co., Ltd.
Covance Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON plc
IQVIA Holdings Inc.
Jubilant Life Sciences Ltd.
Lonza Group AG
Novotech Pty Ltd.
PAREXEL International Corporation
Patheon Inc.
Pfizer CentreSource
PPD, Inc.
Recipharm AB
Samsungbioepis Co,. Ltd.
Syneos Health Inc.
WuXi AppTec Inc.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER